Venture Life Group
VLG · AIM · Personal Care, Drug and Grocery Stores · mcap £84m · 69.0p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 06 Oct 26 | Transfer of Treasury Shares
Venture Life Group PLC (AIM: VLG), a leader in product innovation, development and commercialisation within the global consumer healthcare sector, announces that today the Company transferred 110,000 ordinary shares of 0 |
+0.0% | |
| 29 Sep 26 | Results | Final Results and CEO Succession
Final results for the seventeen month period ended 31 May 2026 |
−5.4% |
| 24 Sep 26 | Investor Presentation via Investor Meet Company
Venture Life (AIM: VLG) is pleased to announce that Jerry Randall (CEO), Daniel Wells (CFO) and Kate Bache (Chief Innovation & Marketing Officer) will provide a live presentation relating to the Final Results for the 17- |
+0.0% | |
| 20 Aug 26 | Share Buyback Programme
Venture Life Group plc (AIM: VLG), a recognised leader in proactive healthy longevity, product innovation, development, and commercialisation within the global consumer healthcare sector, is pleased to announce the decis |
+3.1% | |
| 27 Jul 26 | Transfer of Treasury Shares
Venture Life Group PLC (AIM: VLG), a leader in product innovation, development and commercialisation within the global consumer healthcare sector, announces that it has today transferred 70,000 ordinary shares of 0.3p ea |
+0.0% | |
| 22 Jul 26 | Transfer of Treasury Shares
Transfer of Treasury Shares & Transaction in Own Shares |
+0.0% | |
| 14 Jul 26 | Transfer of Treasury Shares
Venture Life Group PLC (AIM: VLG), a leader in product innovation, development and commercialisation within the global consumer healthcare sector, announces that on 13th July 2026 the Company transferred 129,000 ordinary |
+3.0% | |
| 13 Jul 26 | Transfer of Treasury Shares
Venture Life Group PLC (AIM: VLG), a leader in product innovation, development and commercialisation within the global consumer healthcare sector, announces that on 10th July 2026 the Company transferred 257,500 ordinary |
+0.0% | |
| 30 Jun 26 | Trading update | Full Year Trading Update
Revenue and Adjusted EBITDA in line with management expectations |
−0.8% |
| 03 Jun 26 | Acquisition of FemiClear and CUROXEN
Venture Life (AIM: VLG), a recognised leader in proactive longevity, health innovation and global commercialisation within the consumer healthcare sector, is pleased to announce the acquisition of FemiClear, and CUROXEN |
+15.0% | |
| 31 Mar 26 | Results | Half-year Results
Unaudited Interim Results for the 12-month period ended 31 December 2025 |
−2.9% |
| 26 Mar 26 | Investor Presentation via Investor Meet Company
Venture Life (AIM: VLG) is pleased to announce that Jerry Randall (CEO), Daniel Wells (CFO) and Kate Bache (Chief Innovation & Marketing Officer) will provide a live presentation relating to the Interim Results for the 1 |
−0.4% | |
| 12 Feb 26 | PCA Dealing
Venture Life Group PLC (AIM: VLG), a recognised leader in proactive healthy, product innovation, development, and commercialisation within the global consumer healthcare sector, announces that it was notified on 11 Febru |
−0.7% | |
| 30 Jan 26 | Exercise of Share Options & Total Voting Rights
Exercise of Share Options & Total Voting Rights |
−2.2% | |
| 26 Jan 26 | Trading update | Trading Update
Venture Life (AIM: VLG), a leader in product innovation, development and commercialisation within the global consumer healthcare sector, announces a trading update for the twelve-month period ended 31 December 2025 (the |
+2.3% |
| 20 Jan 26 | Exercise of Share Options & Total Voting Rights
Exercise of Share Options & Total Voting Rights |
+1.2% | |
| 18 Dec 25 | Exercise of Share Options & Total Voting Rights
Exercise of Share Options & Total Voting Rights |
+1.5% | |
| 09 Dec 25 | Sale of Non-Core Products
Sale of non-core products for up to £4.5m in cash on a cash free, debt free basis |
+2.1% |
Company filings. Not investment advice.